Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

Authors :: Simonetta Mocci
Matthew D. Hellmann
David S. Shames
Priti S. Hegde
Alan Sandler
Lukas C. Amler
Craig Cummings
Roel Funke
Vincent Leveque
Naiyer A. Rizvi
Marcus Ballinger
Susan Flynn
Geetha Shankar
Wei Zou
Alexander I. Spira
Marcin Kowanetz
G.M. Frampton
Garret Hampton
Daniel Waterkamp
Source :: Annals of Oncology. 27:vi23
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: 0301 basic medicine
Oncology
medicine.medical_specialty
business.industry
Hematology
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Atezolizumab
030220 oncology & carcinogenesis
Internal medicine
Mutation (genetic algorithm)
medicine
In patient
business

Full Text Access

Tools